Literature DB >> 16505462

Hepatitis C: a review for primary care physicians.

Tom Wong1, Samuel S Lee.   

Abstract

Primary care physicians see many of the estimated 250 000 Canadians chronically infected with the hepatitis C virus (HCV). Of this number, about one-third are unaware they are infected, which constitutes a large hidden epidemic. They continue to spread HCV unknowingly and cannot benefit from advances in antiviral therapy that may clear them of the virus. Many HCV-infected people remain asymptomatic, which means it is important to assess for risk factors and test patients accordingly. The third-generation enzyme immunoassay for HCV antibodies is a sensitive and specific test, although the presence of the virus can be confirmed by polymerase chain reaction testing for HCV RNA in some circumstances. Pegylated interferon-alpha and ribavirin combination therapy clears the virus in about 45%-80% of patients, depending on viral genotype. Preventive strategies and counselling recommendations are also reviewed.

Entities:  

Mesh:

Year:  2006        PMID: 16505462      PMCID: PMC1389829          DOI: 10.1503/cmaj.1030034

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  148 in total

1.  Hepatitis C in hospital employees with needlestick injuries.

Authors:  K Kiyosawa; T Sodeyama; E Tanaka; Y Nakano; S Furuta; K Nishioka; R H Purcell; H J Alter
Journal:  Ann Intern Med       Date:  1991-09-01       Impact factor: 25.391

2.  Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.

Authors:  Fabrice Carrat; Firouzé Bani-Sadr; Stanislas Pol; Eric Rosenthal; Françoise Lunel-Fabiani; Asmae Benzekri; Patrice Morand; Cécile Goujard; Gilles Pialoux; Lionel Piroth; Dominique Salmon-Céron; Claude Degott; Patrice Cacoub; Christian Perronne
Journal:  JAMA       Date:  2004-12-15       Impact factor: 56.272

3.  Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.

Authors:  P Marcellin; N Boyer; A Gervais; M Martinot; M Pouteau; C Castelnau; A Kilani; J Areias; A Auperin; J P Benhamou; C Degott; S Erlinger
Journal:  Ann Intern Med       Date:  1997-11-15       Impact factor: 25.391

4.  The relationship between therapeutic injections and high prevalence of hepatitis C infection in Hafizabad, Pakistan.

Authors:  S P Luby; K Qamruddin; A A Shah; A Omair; O Pahsa; A J Khan; J B McCormick; F Hoodbhouy; S Fisher-Hoch
Journal:  Epidemiol Infect       Date:  1997-12       Impact factor: 2.451

5.  Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C.

Authors:  F Pessione; F Degos; P Marcellin; V Duchatelle; C Njapoum; M Martinot-Peignoux; C Degott; D Valla; S Erlinger; B Rueff
Journal:  Hepatology       Date:  1998-06       Impact factor: 17.425

6.  Is hepatitis C virus infection a trigger of porphyria cutanea tarda?

Authors:  C Herrero; A Vicente; M Bruguera; M G Ercilla; J M Barrera; J Vidal; J Terés; J M Mascaró; J Rodés
Journal:  Lancet       Date:  1993-03-27       Impact factor: 79.321

7.  Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: an evaluation.

Authors:  G Larcos; H Sorokopud; G Berry; G C Farrell
Journal:  AJR Am J Roentgenol       Date:  1998-08       Impact factor: 3.959

8.  The declining risk of post-transfusion hepatitis C virus infection.

Authors:  J G Donahue; A Muñoz; P M Ness; D E Brown; D H Yawn; H A McAllister; B A Reitz; K E Nelson
Journal:  N Engl J Med       Date:  1992-08-06       Impact factor: 91.245

9.  Hepatitis C virus infection in patients with essential mixed cryoglobulinemia.

Authors:  R Misiani; P Bellavita; D Fenili; G Borelli; D Marchesi; M Massazza; G Vendramin; B Comotti; E Tanzi; G Scudeller
Journal:  Ann Intern Med       Date:  1992-10-01       Impact factor: 25.391

10.  Treatment of chronic hepatitis C in HIV-infected patients with interferon alpha-2b plus ribavirin.

Authors:  Mayte Pérez-Olmeda; Vincent Soriano; Victor Asensi; Dolores Morales; Miriam Romero; Anna Ochoa; Fausto Sánchez-Montero; Miguel Santin; Josep Guardiola; Jesús Blanch; Marina Núñez; Inmaculada Jiménez-Nácher; Javier García-Samaniego
Journal:  AIDS Res Hum Retroviruses       Date:  2003-12       Impact factor: 2.205

View more
  29 in total

1.  Hepatitis C virus infection.

Authors:  Michael Fralick; Jordan J Feld
Journal:  CMAJ       Date:  2015-08-24       Impact factor: 8.262

2.  Hepatitis C: reviewing the options.

Authors:  Michal R Pijak
Journal:  CMAJ       Date:  2006-07-04       Impact factor: 8.262

3.  Hepatitis C: reviewing the options.

Authors:  Sujoy Khan; W A C Sewell
Journal:  CMAJ       Date:  2006-07-04       Impact factor: 8.262

4.  Hepatitis C virus infection in Canada's First Nations people: a growing problem.

Authors:  Matthew D Sadler; Samuel S Lee
Journal:  Can J Gastroenterol       Date:  2013-06       Impact factor: 3.522

Review 5.  Advances in nucleoside monophosphate prodrugs as anti-HCV agents.

Authors:  Drew R Bobeck; Raymond F Schinazi; Steven J Coats
Journal:  Antivir Ther       Date:  2010

6.  Role of primary care providers in hepatitis C prevention and care: one step away from evidence-based practice.

Authors:  Andreea Adelina Artenie; Julie Bruneau; Annie Lévesque; Jean-Marie Bamvita Wansuanganyi
Journal:  Can Fam Physician       Date:  2014-10       Impact factor: 3.275

7.  Recommendations on hepatitis C screening for adults.

Authors:  Roland Grad; Brett Thombs; Marcello Tonelli; Maria Bacchus; Richard Birtwhistle; Scott Klarenbach; Harminder Singh; Veronique Dorais; Nathalie Holmes; Wendy Martin; Rachel Rodin; Alejandra Jaramillo Garcia
Journal:  CMAJ       Date:  2017-04-24       Impact factor: 8.262

8.  A substituted tetrahydro-tetrazolo-pyrimidine is a specific and novel inhibitor of hepatitis B virus surface antigen secretion.

Authors:  Anne Marie Dougherty; Haitao Guo; Gael Westby; Yuanjie Liu; Ender Simsek; Ju-Tao Guo; Anand Mehta; Pamela Norton; Baohua Gu; Timothy Block; Andrea Cuconati
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

9.  Capacity enhancement of hepatitis C virus treatment through integrated, community-based care.

Authors:  Warren D Hill; Gail Butt; Maria Alvarez; Mel Krajden
Journal:  Can J Gastroenterol       Date:  2008-01       Impact factor: 3.522

Review 10.  Managing chronic hepatitis C in the difficult-to-treat patient.

Authors:  Nyingi Kemmer; Guy W Neff
Journal:  Liver Int       Date:  2007-12       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.